According to ImmunoGen
's latest financial reports the company has $0.60 Billion USD in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.27 B | -42.53% |
2021-12-31 | $0.47 B | 62.92% |
2020-12-31 | $0.29 B | 66.75% |
2019-12-31 | $0.17 B | -32.8% |
2018-12-31 | $0.26 B | -1.82% |
2017-12-31 | $0.26 B | |
2016-06-30 | $0.24 B | -11.9% |
2015-06-30 | $0.27 B | 95.49% |
2014-06-30 | $0.14 B | -27.03% |
2013-06-30 | $0.19 B | 21.14% |
2012-06-30 | $0.16 B | -15.83% |
2011-06-30 | $0.19 B | 73.35% |
2010-06-30 | $0.11 B | 55.08% |
2009-06-30 | $71.12 M | 48.58% |
2008-06-30 | $47.87 M | -19.81% |
2007-06-30 | $59.7 M | -20.42% |
2006-06-30 | $75.02 M | -17.16% |
2005-06-30 | $90.56 M | -4.28% |
2004-06-30 | $94.61 M | -6.58% |
2003-06-30 | $0.10 B | -26.53% |
2002-06-30 | $0.13 B | 45.87% |
2001-06-30 | $94.49 M | 445.3% |
2000-06-30 | $17.32 M | 220.91% |
1999-06-30 | $5.4 M | 217.65% |
1998-06-30 | $1.7 M | 0% |
1997-06-30 | $1.7 M | -39.29% |
1996-06-30 | $2.8 M |